Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.

Frontiers in neuroscience

Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, Khlebtovsky A, Lerer B, Djaldetti R.
PMID: 23596382
Front Neurosci. 2013 Apr 15;7:52. doi: 10.3389/fnins.2013.00052. eCollection 2013.

Parkinson's disease (PD) is slowly progressive, and heterogeneity of its severity among individuals may be due to endogenous mechanisms that counterbalance the striatal dopamine loss. In this perspective paper, we introduce a neuroimaging-genetic approach to identify genetic variants, which...

Cite
Greenbaum L, Lorberboym M, Melamed E, et al. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Front Neurosci. 2013;7:52doi: 10.3389/fnins.2013.00052.
Greenbaum, L., Lorberboym, M., Melamed, E., Rigbi, A., Barhum, Y., Kohn, Y., Khlebtovsky, A., Lerer, B., & Djaldetti, R. (2013). Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Frontiers in neuroscience, 752. https://doi.org/10.3389/fnins.2013.00052
Greenbaum, Lior, et al. "Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease." Frontiers in neuroscience vol. 7 (2013): 52. doi: https://doi.org/10.3389/fnins.2013.00052
Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, Khlebtovsky A, Lerer B, Djaldetti R. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Front Neurosci. 2013 Apr 15;7:52. doi: 10.3389/fnins.2013.00052. eCollection 2013. PMID: 23596382; PMCID: PMC3625833.
Copy Download .nbib Format: NLM
Chronic Myelogenous Leukemia Associated with Extranodal B-Cell Lymphoma.

Leukemia & lymphoma

Cohen AM, Mittelman M, Sandbank J, Shabtai F, Lapidot M, Djaldetti M.
PMID: 27467852
Leuk Lymphoma. 1991;5(4):287-91. doi: 10.3109/10428199109068139.

A 75-year-old man is reported with a 10 year-history of villous adenoma of the colon and carcinoma in situ treated by hemicolectomy. Seven years later, he developed chronic myelogenous leukemia (CML). After a 3-month course of busulfan he was...

Cite
Cohen AM, Mittelman M, Sandbank J, et al. Chronic Myelogenous Leukemia Associated with Extranodal B-Cell Lymphoma. Leuk Lymphoma. 1991;5(4):287-91doi: 10.3109/10428199109068139.
Cohen, A. M., Mittelman, M., Sandbank, J., Shabtai, F., Lapidot, M., & Djaldetti, M. (1991). Chronic Myelogenous Leukemia Associated with Extranodal B-Cell Lymphoma. Leukemia & lymphoma, 5(4), 287-91. https://doi.org/10.3109/10428199109068139
Cohen, A M, et al. "Chronic Myelogenous Leukemia Associated with Extranodal B-Cell Lymphoma." Leukemia & lymphoma vol. 5,4 (1991): 287-91. doi: https://doi.org/10.3109/10428199109068139
Cohen AM, Mittelman M, Sandbank J, Shabtai F, Lapidot M, Djaldetti M. Chronic Myelogenous Leukemia Associated with Extranodal B-Cell Lymphoma. Leuk Lymphoma. 1991;5(4):287-91. doi: 10.3109/10428199109068139. PMID: 27467852.
Copy Download .nbib Format: NLM
Sensory symptoms in Parkinson's disease.

Handbook of clinical neurology

Djaldetti R, Melamed E.
PMID: 18808923
Handb Clin Neurol. 2007;83:377-84. doi: 10.1016/S0072-9752(07)83016-8.

No abstract available.

Cite
Djaldetti R, Melamed E. Sensory symptoms in Parkinson's disease. Handb Clin Neurol. 2007;83:377-84doi: 10.1016/S0072-9752(07)83016-8.
Djaldetti, R., & Melamed, E. (2007). Sensory symptoms in Parkinson's disease. Handbook of clinical neurology, 83377-84. https://doi.org/10.1016/S0072-9752(07)83016-8
Djaldetti, Ruth, and Melamed, Eldad. "Sensory symptoms in Parkinson's disease." Handbook of clinical neurology vol. 83 (2007): 377-84. doi: https://doi.org/10.1016/S0072-9752(07)83016-8
Djaldetti R, Melamed E. Sensory symptoms in Parkinson's disease. Handb Clin Neurol. 2007;83:377-84. doi: 10.1016/S0072-9752(07)83016-8. PMID: 18808923.
Copy Download .nbib Format: NLM
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

Parkinsonism & related disorders

Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y.
PMID: 34619438
Parkinsonism Relat Disord. 2021 Oct;91:139-145. doi: 10.1016/j.parkreldis.2021.09.024. Epub 2021 Oct 01.

INTRODUCTION: ND0612 is a continuous, subcutaneous levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.METHODS: This was a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics of ND0612 in PD patients on...

Cite
Giladi N, Gurevich T, Djaldetti R, et al. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021;91:139-145doi: 10.1016/j.parkreldis.2021.09.024.
Giladi, N., Gurevich, T., Djaldetti, R., Adar, L., Case, R., Leibman-Barak, S., Sasson, N., & Caraco, Y. (2021). ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism & related disorders, 91139-145. https://doi.org/10.1016/j.parkreldis.2021.09.024
Giladi, Nir, et al. "ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study." Parkinsonism & related disorders vol. 91 (2021): 139-145. doi: https://doi.org/10.1016/j.parkreldis.2021.09.024
Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021 Oct;91:139-145. doi: 10.1016/j.parkreldis.2021.09.024. Epub 2021 Oct 01. PMID: 34619438.
Copy Download .nbib Format: NLM
The parkinsonian toxin MPTP: action and mechanism.

Restorative neurology and neuroscience

Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G.
PMID: 12671216
Restor Neurol Neurosci. 2000;16(2):135-142.

MPTP causes damage to substantia nigra pars compacta (SNpc) dopaminergic (DA) neurons as seen in Parkinson's disease (PD). After sys-temic administration of MPTP, its active metabolite, MPP +, accumulates within SNpc DA neurons, where it inhibits ATP production and...

Cite
Przedborski S, Jackson-Lewis V, Djaldetti R, et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000;16(2):135-142
Przedborski, S., Jackson-Lewis, V., Djaldetti, R., Liberatore, G., Vila, M., Vukosavic, S., & Almer, G. (2000). The parkinsonian toxin MPTP: action and mechanism. Restorative neurology and neuroscience, 16(2), 135-142.
Przedborski, Serge, et al. "The parkinsonian toxin MPTP: action and mechanism." Restorative neurology and neuroscience vol. 16,2 (2000): 135-142.
Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000;16(2):135-142. PMID: 12671216.
Copy Download .nbib Format: NLM
[TOWARD A PRECISE METHODOLOGICAL DEFINITION OF MENTAL DISEASES AND RELATED PROBLEMS].

Folia medica

DJALDETTI A, BOYADJIEVA M.
PMID: 14292969
Folia Med (Plovdiv). 1964;6:104-7.

No abstract available.

Cite
DJALDETTI A, BOYADJIEVA M. POUR UNE DEFINITION METHODOLOGIQUE PLUS EXACITE DE LA MALADIE MENTAL ET CERTAINES QUESTIONS LIEES A ELLE. [TOWARD A PRECISE METHODOLOGICAL DEFINITION OF MENTAL DISEASES AND RELATED PROBLEMS]. Folia Med (Plovdiv). 1964;6:104-7
DJALDETTI, A., & BOYADJIEVA, M. (1964). POUR UNE DEFINITION METHODOLOGIQUE PLUS EXACITE DE LA MALADIE MENTAL ET CERTAINES QUESTIONS LIEES A ELLE. [TOWARD A PRECISE METHODOLOGICAL DEFINITION OF MENTAL DISEASES AND RELATED PROBLEMS]. Folia medica, 6104-7.
DJALDETTI, A, and BOYADJIEVA, M. "POUR UNE DEFINITION METHODOLOGIQUE PLUS EXACITE DE LA MALADIE MENTAL ET CERTAINES QUESTIONS LIEES A ELLE." [TOWARD A PRECISE METHODOLOGICAL DEFINITION OF MENTAL DISEASES AND RELATED PROBLEMS]. Folia medica vol. 6 (1964): 104-7.
DJALDETTI A, BOYADJIEVA M. POUR UNE DEFINITION METHODOLOGIQUE PLUS EXACITE DE LA MALADIE MENTAL ET CERTAINES QUESTIONS LIEES A ELLE. [TOWARD A PRECISE METHODOLOGICAL DEFINITION OF MENTAL DISEASES AND RELATED PROBLEMS]. Folia Med (Plovdiv). 1964;6:104-7. French. PMID: 14292969.
Copy Download .nbib Format: NLM
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

Parkinsonism & related disorders

Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y.
PMID: 34619438
Parkinsonism Relat Disord. 2021 Oct;91:139-145. doi: 10.1016/j.parkreldis.2021.09.024. Epub 2021 Oct 01.

INTRODUCTION: ND0612 is a continuous, subcutaneous levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.METHODS: This was a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics of ND0612 in PD patients on...

Cite
Giladi N, Gurevich T, Djaldetti R, et al. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021;91:139-145doi: 10.1016/j.parkreldis.2021.09.024.
Giladi, N., Gurevich, T., Djaldetti, R., Adar, L., Case, R., Leibman-Barak, S., Sasson, N., & Caraco, Y. (2021). ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism & related disorders, 91139-145. https://doi.org/10.1016/j.parkreldis.2021.09.024
Giladi, Nir, et al. "ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study." Parkinsonism & related disorders vol. 91 (2021): 139-145. doi: https://doi.org/10.1016/j.parkreldis.2021.09.024
Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021 Oct;91:139-145. doi: 10.1016/j.parkreldis.2021.09.024. Epub 2021 Oct 01. PMID: 34619438.
Copy Download .nbib Format: NLM
Modulators affecting the immune dialogue between human immune and colon cancer cells.

World journal of gastrointestinal oncology

Djaldetti M, Bessler H.
PMID: 24834143
World J Gastrointest Oncol. 2014 May 15;6(5):129-38. doi: 10.4251/wjgo.v6.i5.129.

The link between chronic inflammation and colorectal cancer has been well established. The events proceeding along tumorigenesis are complicated and involve cells activated at the cancer microenvironment, tumor infiltrating polymorphonuclears, immune cells including lymphocyte subtypes and peripheral blood mononuclear...

Cite
Djaldetti M, Bessler H. Modulators affecting the immune dialogue between human immune and colon cancer cells. World J Gastrointest Oncol. 2014;6(5):129-38doi: 10.4251/wjgo.v6.i5.129.
Djaldetti, M., & Bessler, H. (2014). Modulators affecting the immune dialogue between human immune and colon cancer cells. World journal of gastrointestinal oncology, 6(5), 129-38. https://doi.org/10.4251/wjgo.v6.i5.129
Djaldetti, Meir, and Bessler, Hanna. "Modulators affecting the immune dialogue between human immune and colon cancer cells." World journal of gastrointestinal oncology vol. 6,5 (2014): 129-38. doi: https://doi.org/10.4251/wjgo.v6.i5.129
Djaldetti M, Bessler H. Modulators affecting the immune dialogue between human immune and colon cancer cells. World J Gastrointest Oncol. 2014 May 15;6(5):129-38. doi: 10.4251/wjgo.v6.i5.129. PMID: 24834143; PMCID: PMC4021329.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries